Page 9 - Program On Regulation News Today

In his resignation letter, Dr. Aaron Kesselheim calls it "probably the worst drug approval decision in recent U.S. history." An FDA official says the agency found the benefits outweighed the risks.

Three experts have now resigned from a Food and Drug Administration advisory committee after the agency approved an Alzheimer's drug called Aduhelm

In his resignation letter, Dr. Aaron Kesselheim calls it "probably the worst drug approval decision in recent U.S. history." An FDA official says the agency found the benefits outweighed the risks.

Three experts have now resigned from a Food and Drug Administration advisory committee after the agency approved an Alzheimer's drug called Aduhelm

 E-Mail WHO Benjamin Rome, MD, Instructor of Medicine at Harvard Medical School and researcher in the Program On Regulation, Therapeutics, And Law (PORTAL) in the Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Womens Hospital; corresponding author of a paper published in WHAT When drug manufacturers raise the list price for brand-name prescription drugs, do patients out-of-pocket costs rise too? A new study published in JAMA Network Open by Dr. Benjamin Rome and collea...